ADAMTSL4, as a secreted glycoprotein, is a novel human biomarker in the regulation of immune-associated treatment, participating in microfibril formation and function (Hubmacher and Apte, 2015), and it is closely linked to immune-related biological processes in glioblastoma multiform (GBM) (Hubmacher and Apte, 2015). This evidence concerns the gene ADAMTSL4 and glioblastoma.